Genmab — Oktober 2019
-
-
Synes også den grafiske fremstilling af salgsudvikling ser spændende ud
- er lidt talnørd så er der mon en der ved hvor kan jeg se de enkelte tal der indgår i søjlerne -
pensionisten: tak for info
-
-
H.C. Wainwrigh
t raises target price to USD 25 from USD 24 -
AQR har reduceret short fra 1,29% til 1,19%
-
Nektar Therapeutics starts a new trial, also with Dara https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-initiation-first-human-phase-1
-
In a preclinical lymphoma model where single agent daratumumab was ineffective, NKTR-255 treatment, in combination with daratumumab, increased NK cell numbers and activity in bone marrow tissue and enhanced ADCC-mediated tumor cell clearance in the bone marrow compartment.4
-
Nektar havde denne på AACR
https://www.nektar.com/application/files/7215/5420/5270/AACR2019-ABS3265-Final.pdf -
https://nyheder.tv2.dk/business/2019-10-16-danske-pensionskasser-er-tungt-investeret-i-udskaeldt-amerikansk-medicinalfirma JNJ vil hænge i bremsen i lang tid grundet restssager i titusindevis. Tvivler på at de vil få råd til at købe Genmab de næste mange år.....
-
De mener selv at de har fat i den lange ende, men nu må vi se.
-
Johnson & Johnson sætter ingen penge til side trods 100.000 søgsmål
Johnson & Johnson står foran mere end 100.000 søgsmål for sin produktsikkerhed og sine markedstaktikker, men har alligevel ikke tænkt sig at sætte penge til side til at betale erstatninger.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind